CDR-Life Updates Pipeline Progress for M-gager® Solid Tumor Treatments
CDR-Life has announced key advancements in its M-gager® programs targeting solid tumors, highlighting notable progress in its mission to develop innovative antibody fragment-based immunotherapies for challenging cancers. First Patient Dosed with CDR404 CDR-Life has dosed its first patient with CDR404,…
Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection in the U.S.
Rising Pharmaceuticals, Inc. has announced the commercial launch of Edetate calcium disodium injection. Despite a current shortage of this product in the U.S., Rising’s version remains available. Rising Pharmaceuticals, Inc. has announced the availability of Edetate calcium disodium injection, which…
Masimo and Google Team Up to Create Reference Platform for Advanced Wear OS Smartwatches
Masimo (NASDAQ: MASI), a leading innovator in medical technology, has announced a new partnership with Google to develop a reference platform for Wear OS by Google™ smartwatches. This collaboration will integrate Masimo’s advanced biosensing technologies, honed through decades of hospital…
SamanTree Medical’s Histolog® Scanner Receives FDA Clearance, Revolutionizing Tissue Imaging in the U.S.
SamanTree Medical, a pioneer in surgical imaging technology, has announced that its Histolog® Scanner has received FDA 510(k) clearance. This groundbreaking Swiss device offers real-time, high-resolution imaging of fresh tissue surfaces, enabling detailed visualization of internal microstructures such as cells,…
Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine is designed to protect against the JN.1 lineage of Omicron…
Tivic Health Names Lisa Wolf Interim CFO
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a leader in bioelectronic medicine, has appointed Lisa Wolf as its Interim Chief Financial Officer (CFO), effective October 1, 2024. Wolf succeeds Kimberly Bambach, who has served as interim CFO since April 2023 and…
GN BODYDOCTOR Kegel Exerciser: Effective for Pelvic Muscle Health
As people age or experience life events like childbirth, maintaining pelvic muscle strength can be challenging. While Kegel exercises are a well-known solution, they are often overlooked. Developed by Dr. Arnold Kegel in 1948, these exercises were initially intended to…
Advanced eClinical Training and The Education Fund Partner to Enhance Healthcare Worker Education
Advanced eClinical Training (ACT), a top provider of online career certification, has joined forces with the SEIU-UHW West & Joint Employer Education Fund (The Education Fund), which offers employer-funded education, training, and career support for union members in healthcare. This…
ENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases
Results from the DESTINY-Breast12 phase 3b/4 trial reveal that ENHERTU® (trastuzumab deruxtecan) demonstrated significant clinical activity in HER2-positive metastatic breast cancer patients with brain metastases who had received up to two prior lines of therapy. These findings will be presented…
LifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation
On August 28, 2024, Dongguk University Startup Technology Institute, LifestyledAI Co., Ltd., and UMUST R&D signed a joint MOU to collaborate on advancing global deep tech and healthcare initiatives. The partnership will leverage LifestyledAI’s innovative, proprietary AI technologies, currently patent-pending,…
Massive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access
Massive Bio, an AI-powered clinical trial matching platform, and Foundation Medicine have announced a strategic partnership to expand patient access to advanced clinical trials. The collaboration combines Massive Bio’s patient-matching technology with Foundation Medicine’s expertise in next-generation sequencing (NGS) and…
FDA Approves Ocrevus Zunovo™: First Twice-Yearly 10-Minute Injection for MS
Genentech, part of the Roche Group, announced that the U.S. FDA has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first twice-yearly, 10-minute subcutaneous injection administered…